Abstract
Pancreatic cancer has very poor prognosis and has a very low five-year survival rate of the order of 5%. This is so because of the lack of major clinical symptoms and reliable detection markers. Recently, it has been realized that hypoxia is one of the major contributors to tumor growth, malignancy, invasion, propagation, metastasis, and resistance to therapy in several solid tumors including the pancreatic cancer. Understandably, it has gained even more importance in pancreatic cancer and is considered as the primary target for its therapy in the recent times since it has been identified as the major determinant of cancer malignancy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
